Addition of Nitazoxanide to Standard Clarithromycin Based Triple Therapy for 2 Weeks Effectively Eradicates Treatment-Naive Helicobacter Pylori Infection. A Single Centre prospective, open-label study.
BACKGROUND: The increasing prevalence of antibiotic-resistant strains of Helicobacter pylori (H. pylori) led to reduced success with traditional H. pylori treatments. This warrants further evaluation of other treatment options. One such treatment regimen of interest is nitazoxanide containing regime...
| Published in: | Middle East Journal of Digestive Diseases Vol. 14; no. 1; pp. 77 - 85 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | research tables/charts Journal Article |
| Published: |
Iranian Association of Gastroenterology & Hepatology
Jan2022
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=157181196&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 157181196 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 20085230 BG4K jtl: Middle East Journal of Digestive Diseases issn: 20085230 maglogo: N pubinfo: dt: Jan2022 vid: 14 iid: 1 pid: 70725 pub: Iranian Association of Gastroenterology & Hepatology artinfo: ui: 157181196 157181196 157181196 10.34172/mejdd.2022.259 157181196 ppf: 77 ppct: 8 formats: fmt: @attributes: type: P tig: atl: Addition of Nitazoxanide to Standard Clarithromycin Based Triple Therapy for 2 Weeks Effectively Eradicates Treatment-Naive Helicobacter Pylori Infection. A Single Centre prospective, open-label study. aug: au: Jha, Sanjeev K. Kumar, Ravikant Kumar, Amitesh Purkayastha, Shubham Keshri, Ravi Kumar, Saurabh Singh, Aditya Vardhan affil: Additional Professor, Department of Gastroenterology, Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, Bihar, India sug: subj: Clarithromycin Therapeutic Use Helicobacter Infections Drug Therapy Drug Efficacy Antiparasitic Agents Therapeutic Use Drug Therapy, Combination Human Prospective Studies Nonexperimental Studies Medication Compliance Clarithromycin Adverse Effects Disease Eradication ab: BACKGROUND: The increasing prevalence of antibiotic-resistant strains of Helicobacter pylori (H. pylori) led to reduced success with traditional H. pylori treatments. This warrants further evaluation of other treatment options. One such treatment regimen of interest is nitazoxanide containing regimen. In this study, we evaluated the efficacy of the addition of nitazoxanide to clarithromycin-based triple therapy in patients with H. pylori infection. METHODS: In this single-center prospective observational trial, patients with H. pylori infection were treated with a regimen comprising of nitazoxanide 1000 mg, amoxicillin 2000 mg, clarithromycin 1000 mg, and esomeprazole 80 mg per day (NACE regimen) for 14 days. Eradication of H. pylori infection was assessed 4 weeks after completion of therapy by using stool antigen assay. Treatment compliance and adverse effects were also evaluated. RESULTS: Out of 111 patients who entered into the study for final analysis, H. pylori eradication was achieved in 93.7% (104 out of 111) patients in per-protocol analysis and 90.4% (104 out of 115) patients in intention to treat analysis. The treatment regimen was well tolerated. CONCLUSION: The addition of nitazoxanide to standard clarithromycin-based triple therapy effectively eradicates H. pylori infection. This regimen is safe and well tolerated. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|